Kornimate/medical-research-clean huggingface dataset:
quantification of myocardial blood flow using dynamic pet/cta fused imagery

Conditions: Coronary Artery Disease

Summary: this observational prospective clinical study is to develop software tools to fuse coronary anatomy data obtained from ct coronary angiography with dynamic pet data to noninvasively measure absolute myocardial blood flow, flow reserve and relative flow reserve across specific coronary lesions. results will be compared to those obtained invasively in the catheterization laboratory.

this observational prospective clinical study is to develop software tools to fuse coronary anatomy data obtained from ct coronary angiography with dynamic pet data to noninvasively measure absolute myocardial blood flow, flow reserve and relative flow reserve across specific coronary lesions. these results will be compared to those obtained invasively in the catheterization laboratory. the long-term objective of the study is to improve the care of cardiac patients by developing, validating and implementing clinically computer-based methods to noninvasively determine the physiological significance of specific coronary lesions using methods to fuse and quantify multi-modality cardiac imagery.

Eligibility criteria:
inclusion criteria: * adult (≥18 years of age) - as the research topic to be studied is irrelevant to children * written consent form * patients with prior dynamic pet or ccta or ica for any indications exclusion criteria: * previous history of allergy to iodinated contrast * previous cabg * serum creatinine levels \>1.8 mg/dl unless patient has end stage kidney disease, not producing any urine and dialysis * history of claustrophobia (ct tunnel length of more than 100 cm) * significant arrhythmias or tachycardia * history of frequent asthma attacks or acting wheezing * second- and third-degree heart block * systolic blood pressure of \< 90 mmhg * heart failure with nyha class iii-iv at the time of the ccta procedure. if it is deemed that, the heart failure has been resolved or the patient was incorrectly labeled as having heart failure the radiology physician in charge will verify the absence of heart failure at the time of ccta and perform the procedure. * recent myocardial infarction * if the patient has been diagnosed with unstable angina within 24 hours prior to ccta, the patient will not be consented. if the patient does not have the diagnosis of unstable angina and is consented, the radiology physician in charge will verify the absence of unstable angina at the time of ccta. * patients enrolled and consented for the invasive measurements that at the time of catheterization exhibit severe vessel disease and/or obstructions that prevent the operator from safely conducting the measurements will be removed from the study; further research imaging sessions - if planned - will be canceled and patients indicated as "screen failure" in our enrollment log.

Keywords: fractional flow reserve myocardial blood flow relative flow reserve non-invasive measure cardiac catheterization ct coronary angiography dynamic pet invasive coronary angiography 3d fusion dpet/cta ffrct
intraocular cytokine in recurrence of polypoidal choroidal vasculopathy

Conditions: Exudative Age-related Macular Degeneration; Polypoidal Choroidal Vasculopathy

Summary: changes of intraocular cytokines including vascular endothelial growth factor (vegf) will be measured in recurrence of polypoidal choroidal vasculopathy (pcv) during treatment of ranibizumab.

pcv is regarded as a subtype of age-related macular degeneration (armd), but has several different features such as polypoidal terminal of new vessels, and relative resistance to anti-vegf treatment. other cytokines then vegf are thought to be associated with development and progression of the disease. the aim of the this study is to investigate intraocular cytokines related to recurrence of polypoidal choroidal vasculopathy. aqueous humor will be sampled from the anterior chamber at baseline, after loading injections of ranibizumab and at recurrence. the concentration of various cytokines will be measured in the aqueous humor.

Eligibility criteria:
inclusion criteria: 1. submacular pcv diagnosed based on branching neovascular networks having polypoidal dilatation in icga. 2. presence of exudative changes involving the fovea in oct 3. decreased visual acuity to 20/320 - 20/40 to be primarily the results of pcv in the study eye. 4. willing and able to comply with clinic visits and study-related procedures, and provide a signed informed consent form. exclusion criteria: 1. extramacular pcv. 2. presence of pathologic changes blocking 50% or more area of the lesion in angiography. 3. any anti-vegf treatment in the study eye within 180 days of day 1. 4. previous photodynamic therapy in the study eye. 5. history of intraocular surgery except uncomplicated cataract surgery performed before 90 days or more from day 1. 6. presence of exudative armd requiring anti-vegf treatment in the other eye. 7. presence of other ocular disease that may compromise visual acuity in the study eye. 8. uncontrolled systemic disease. 9. active intraocular or periocular infection. 10. active intraocular inflammation. 11. hypersensitivity to ranibizumab or excipients.
asthma self-management in older adults

Conditions: Asthma; Aged

Summary: asthma self-management is an effective way to improve the outcomes of patients with asthma. however, to be most effective these interventions should be targeted and designed toward a specific population or group. there is currently no asthma self-management intervention directed towards older adults. the hypothesis is that a 6-session asthma self-management intervention will improve the outcomes of older patients with asthma.


Eligibility criteria:
inclusion criteria:: age over 65, physician diagnosed asthma, need for daily asthma control medication, access to a telephone. - exclusion criteria: smoking history greater than 40 pack years, current smoker, mental impairment that would preclude participation in the asthma self management program -

Keywords: asthma aged self care
positron emission tomography using carbon-11 acetate and fludeoxyglucose f 18 in detecting hepatocellular carcinoma (liver cancer) in patients with known or suspected liver cancer

Conditions: Liver Cancer

Summary: rationale: imaging procedures, such as carbon-11 acetate positron emission tomography (pet) and fludeoxyglucose f 18 pet, may improve the ability to detect hepatocellular carcinoma (liver cancer) and allow doctors to plan the most effective treatment. purpose: this clinical trial is studying how well carbon-11 acetate pet and fludeoxyglucose f 18 pet work in detecting cancer in patients with liver cancer.


Eligibility criteria:
inclusion: * biopsy-proved hcc (stage i and ii by conventional staging) or one or more of the following in a patient with clinically documented cirrhosis: * afp \> 200 mg/dl; * a contrast-enhancing tumor mass (\>1 cm) by ct or mri; or * a tumor mass confirmed by arteriography. * patient must provide written informed consent and have completed conventional imaging and staging before initiation of pet imaging. exclusion: * pediatric patients under the age of 18 will be excluded from consideration from this study. * patients with a known prior malignancy (with the exception of basal cell carcinoma of the skin and carcinoma in situ of the cervix) within 5 years will be excluded from entry into the study. however, patients with a prior hcc thought to have a new primary or recurrent hcc are eligible. * pregnant and breastfeeding patients. * patients with poorly controlled diabetes mellitus (fasting blood glucose level \> 200 mg/dl)

Keywords: adult primary hepatocellular carcinoma recurrent adult primary liver cancer localized resectable adult primary liver cancer
an end to the yom kippur (and ramadan) headache

Conditions: Headache

Summary: fasting is a known trigger for headache. people who fast to comply with religious edict have been shown to be prone to headache which becomes more likely to occur with increasing length of fasting, and in people prone to headache. this has been documented as 'yom kippur headache' and 'first of ramadan headache.' we performed a study to test the hypothesis that rofecoxib, a pain medicine and anti-inflammatory, with a prolonged duration of action would prevent or attenuate headache when taken just prior to the complete (no food or drink) 25 hour fast of yom kippur.

introduction: religious fasting is associated with headache. this has been documented as 'yom kippur headache' and ' first- of - ramadan headache.' the cox2 inhibitor, rofecoxib, has been reported effective in preventing perimenstrual migraine and in preventing recurrence of migraine. given its 17 hour half-life, we undertook this study to see whether 50mg rofecoxib taken just prior to the 25 hour yom kippur fast would be effective in preventing headache. methods: we performed a double blind randomized prospective trial of rofecoxib 50mg vs placebo, taken just prior to the onset of fasting, yom kippur 2004. healthy adults aged 18 - 65 were enrolled from the community and from hospital staff. subjects completed a demographic data form and questions regarding headache history and a post-fast survey on headache during the fast, headache intensity, general ease of fasting and side effects. results: we sent out 170 forms of which 105 were completed and returned. of those subjects receiving rofecoxib (n=53), ten or 18.9% vs 34 or 65.4 % of the placebo group (n=52) had headache at some point during the fast (p\<.0001). severity of headache in the treatment group was significantly less for the treatment group (3.45 vs 6.29 on a visual analog scale of 10 (p = .009)). none of those receiving rofecoxib reported a 'more difficult than usual fast' whereas the distribution of difficult to easy fast among the placebo group was more even. conclusion: rofecoxib 50mg taken prior to a twenty five hour ritual fast prevents and attenuates fasting headache.

Eligibility criteria:
inclusion criteria: * history of fasting headache * age 18-65 * intention to fast on yom kippur * history of fasting on yom kippur exclusion criteria: * pregnant or nursing women * known allergy to nsaid type medication * history of chronic illness including heart, kidney, liver or peptic ulcer disease, hypertension, diabetes, lung disease including asthma, or a history of gastrointestinal bleeding.

Keywords: fasting headache cox 2 inhibitors pain prophylaxis
"the efficacy of acacia catechu mouthrinse as antiplaque and antigingivitis agent in fixed orthodontic appliance patients.

Conditions: Gingivitis

Summary: to study effect of acacia catechu a herbal extract;as antipaque and antigingivitis agent in patients with fixed orthodontic appliances.this study is a double blind randomized controlled trial.


Eligibility criteria:
inclusion criteria: * 60 patients in the age group of 15-30 yrs * plaque induced gingivitis having fixed orthodontic appliance exclusion criteria: * seeking any type of antibacterial mouthwash within four weeks of commencement of study, * history of any systemic disease, or past illness, * mentally or physically handicapped, * history of smoking, tobacco chewing, alcohol consumption, * patients with periodontitis, pregnant and lactating women

Keywords: acacia chlorhexidine gingivitis orthodontic appliances.
effect of strategies for the treatment of chronic hepatitis c in colombia

Conditions: Hepatitis C

Summary: hepatitis c is a public health problem and the high cost of the direct-acting antivirals (daa) is one of the main limitations for treatment worldwide. in colombia, the ministry of health and social protection (mohsp) has made progress in addressing hepatitis c problem in order to control the infection and resolve barriers to access to medicines. one of the strategies implemented was the purchase of daa, in association with the paho, and the instauration of the clinical pathway for the treatment of chronic hepatitis c. the implementation of the clinical pathway has required the integration of health care processes and the respective report in the health information systems, allowing a high level of control in the monitoring of the hepatitis c and the subsequent generation of indicators. however, there is limited information on the effects of the strategic purchase and the instauration of the clinical pathway on the costs of care, clinical outcomes and the quality of health care for patients with hepatitis c in colombia. the aim of this study is to establish the effect of strategic purchasing and the clinical pathway for the treatment of chronic hepatitis c, in the clinical results, in the general costs and quality of health care of hepatitis c patients in colombia.

a quasi-experimental design with a non-equivalent control group will be performed, where there will be an intervention group and a control group formed naturally before the investigation. in order to reduce the possible selection bias due to the lack of randomization, the propensity score method will be used. 62 patients will be included in each arm. an estimation and comparison of the direct costs of the care of patients with hepatitis c, before and after the implementation of the strategic purchase and the clinical pathway will be made, using a "top to bottom" method. a questionnaire will be applied to the patients of the intervention group in order to identify barriers and facilitators to hepatitis c health care and patient satisfaction with health care process under the clinical pathway.

Eligibility criteria:
inclusion criteria: * patients diagnosed with chronic hepatitis c confirmed by quantitative hcv rna test * patient affiliated to the contributory system of one health promoting enterprise from colombia. * patients with prescription of pharmacological treatment for hepatitis c. exclusion criteria: * patients with incomplete information in at least one of the following variables: fibrosis, cirrhosis (if applicable), antiviral drug.

Keywords: direct-acting antivirals health services accessibility
probiotics for every newborn trial

Conditions: Colic; Infantile

Summary: the aim of the study is to compare prevention (oral supplementation with the probiotic l. reuteri administered to every newborn within the first week of life for 12 weeks) with treatment-as-needed (supplementation with the probiotic l. reuteri after randomization, to infants who develop excessive cry/fuss up to 12 weeks of age). this is a single site pilot study to assess feasibility for a full trial.

one in five infants experience colic, defined as recurrent and prolonged episodes of crying and fussing with no obvious cause in healthy infants less than 5 months of age. there is evidence to support the role of the probiotic l. reuteri for treatment of colic in breastfed babies and for prevention of colic. however, these two options (prevention vs treatment-as-needed) have not been previously compared head-to-head. the study aims determine if oral supplementation with the probiotic l. reuteri administered to every newborn within the first week of life for 12 weeks (prevention) is superior to treatment-as-needed, as measured by daily cry/fuss duration at 6 and 12 weeks of age.

Eligibility criteria:
inclusion criteria: 1. 1 to 7 days of age 2. term (37 to 41 weeks) 3. breast or formula fed 4. birth weight \> 2500 grams 5. parental consent exclusion criteria: 1. congenital or other medical disorders 2. parents unable to communicate in english or french

Keywords: colic probiotic infant
prehypertension among medical students in visakhapatnam and association with cardiovascular risk factors

Conditions: Prehypertension; Cardiovascular Risk Factors

Summary: student investigator = thakkallapalli zeeshan muzahid. the study aims to assess the prevalence of prehypertension among medical students of andhra medical college, visakhapatnam, india and its association with other cardiovascular risk factors - overweight /obesity, diabetes, lipid profile.

275 medical students will be studied and a history taken and examination done with special emphasis on recording of blood pressure, measurement of height and weight (\& body mass index) and waist circumference in all. glucose tolerance test and fasting lipid profile will be measured in a random selection of 30 prehypertensives and 30 normotensives.

Eligibility criteria:
inclusion criteria: * medical students studying mbbs (bachelor of medicine \& bachelor of surgery) in andhra medical college * clinically healthy * consent to participate in the study exclusion criteria: * known cardiovascular disease * known hypertension * using antihypertensive or other cardiovascular drugs * using any drugs that can affect bp, weight, blood sugar

Keywords: prehypertension prevalence cardiovascular risk factors
individual patient investigational new drug (ind) expanded access program of jnj-68284528, a chimeric antigen receptor t cell (car-t) therapy for participant with multiple myeloma

Conditions: Multiple Myeloma

Summary: the purpose of this individual-patient investigational new drug (ind) single patient request (spr) is to provide participants treatment with jnj-68284528, an investigational product prior to its marketing authorization. such access may be considered for participants with serious/life-threatening diseases or conditions, where there exists no alternative treatments or where alternative treatments have been exhausted.


Eligibility criteria:
a study to assess if mirikizumab is effective and safe compared to secukinumab and placebo in moderate to severe plaque psoriasis (oasis-2)

Conditions: Psoriasis

Summary: the reason for this study is to see how effective and safe mirikizumab is compared to secukinumab and placebo for moderate to severe plaque psoriasis.


Eligibility criteria:
inclusion criteria: * participant must have chronic plaque psoriasis for at least 6 months. exclusion criteria: * participant must not be breastfeeding or nursing woman. * participant must not have had serious, opportunistic, or chronic/recurring infection within 3 months. * participant must not have received a bacillus calmette-guerin (bcg) vaccination within 12 months or received live vaccine(s) (including attenuated live vaccines) within 12 weeks of baseline or intend to receive either during the study. * participant must not have any other skin conditions (excluding psoriasis). * participant must not have previous exposure to cosentyx and any other biologic therapy targeting il-17 (including taltz). * participant must not have received anti-tumor necrosis factor (tnf) biologics within 8 weeks. * participant must not have previous exposure to any biologic therapy targeting il-23 (including stelara).

Keywords: interleukin-23 (il-23)
special drug use surveillance of vonoprazan for "prevention of recurrence of gastric/duodenal ulcer in patients receiving low-dose aspirin: long-term use"

Conditions: Gastric or Duodenal Ulcers

Summary: the purpose of this survey is to investigate the safety and effectiveness of long-term administration of vonoprazan tablets for up to 12 months in the routine clinical setting in patients receiving low-dose aspirin.

the drug being tested in this survey is called vonoprazan. vonoprazan is being tested to treat people who have gastric or duodenal ulcers. this survey will look at the safety and effectiveness of long-term administration of vonoprazan tablets for up to 12 months in the routine clinical setting in patients receiving low-dose aspirin. the survey will enroll approximately 1,000 participants. - vonoprazan 10 mg this multi-center observational survey will be conducted in japan.

Eligibility criteria:
inclusion criteria: * participants with a history of gastric or duodenal ulcer exclusion criteria: * participants with gastric or duodenal ulcer at initiation of vonoprazan therapy * participants with active upper gastrointestinal hemorrhage at initiation vonoprazan therapy * participants with a history of hypersensitivity to any ingredients in vonoprazan tablets * participants receiving atazanavir sulfate or rilpivirine hydrochloride
molecular profiling and molecular labeling of inflammatory myofibroblastic tumor

Conditions: Inflammatory Myofibroblatic Tumor

Summary: gene mutation is a research hotspot in the occurrence of multiple malignant tumors. the somatic gene mutations of many different types of tumors not only help to study the tumorigenesis mechanism and molecular diagnosis, but also can be used as an ideal therapeutic target. large-scale gene profiling studies performed by humans in various types of epithelial tumors have confirmed some new gene mutations. however, there are few reports on the detection of genes related to inflammatory myofibroblastic tumor, and humans have not yet understood its molecular content. therefore, it is necessary to further use molecular detection methods to explore the molecular markers of imt to facilitate its follow-up precise treatment plan.

inflammatory myofibroblastic tumor（imt）is a rare clinical mesenchymal tissue-derived tumor, which can occur in almost all organs and soft tissues, and is characterized by low-grade or borderline tumors. the diagnosis of inflammatory myofibroblastic tumor is mainly based on histopathology and immunohistochemistry. the treatment is resistant to conventional chemotherapy and radiotherapy. the only curative treatment is complete surgical resection. when imt shows typical cellular structural features in pathology, the diagnosis is relatively simple. however, in the presence of atypical features, the accurate diagnosis of imt is still a challenge. therefore, it is necessary to explore a better diagnostic method. secondly, there is no individualized treatment method for aggressive imt patients who relapse and metastasize after surgery. at present, gene mutation is a research hotspot in the occurrence of various malignant tumors. the somatic gene mutations of many different types of tumors not only help to study the tumorigenesis mechanism and molecular diagnosis, but also can be used as an ideal therapeutic target. large-scale gene profiling studies performed by humans in various types of epithelial tumors have confirmed some new gene mutations. however, there are few reports on the detection of inflammatory myofibroblastic tumor, and humans have not yet understood its molecular content. therefore, it is necessary to further use molecular detection methods to explore the molecular markers of imt to facilitate its follow-up precise treatment plan.

Eligibility criteria:
inclusion criteria: 1. from december 2009 to july 2019, patients who were pathologically diagnosed with inflammatory myofibroblastic tumor by sun yat-sen university cancer center； 2. there are related pathological tissue wax blocks in sun yat-sen university cancer center; 3. patient clinical and prognosis tracking data are available. exclusion criteria: the patient who has a clinically detectable second primary malignant tumor.

Keywords: imt gene molecular profiling and molecular markers